Research - Trillium Therapeutics (TSX:TR) (OTC:SCTPF) is an immuno-oncology company developing novel cancer therapeutics. Trillium was founded in 2003 and went public on the Toronto exchange via … Continue Reading
Read NowInsights - On Monday morning, Sarepta Therapeutics (SRPT) held a teleconference concerning regulatory updates for Eteplirsen, the company’s lead drug candidate for Duchenne Muscular Dystrophy. In a Type B … Continue Reading
Read NowResearch - Pain Therapeutics (PTIE) and Durect (DRRX) just announced that Pfizer (PFE) will discontinue development of Remoxy (Extended-Release oxycodone) and will return all rights to Pain Therapeutics. Pain Therapeutics had the rights to … Continue Reading
Read NowRecap - What a week. The iShares NASDAQ Biotechnology (IBB) made new all-time highs and is drastically outpacing the S&P 500, as well as the NASDAQ composite, for the … Continue Reading
Read NowInsights - Shire PLC (SHPG) reported record third quarter revenues on Friday – $1.6 billion and 33% growth over the year-ago quarter – with earnings of $2.93 per share. The company … Continue Reading
Read NowInsights - Tekmira Pharmaceuticals (TKMR) and European drug developer Bavarian Nordic (BAVA.CO) are receiving significant attention in early trading on Wednesday morning with announcements that their two … Continue Reading
Read NowInsights - Agios Pharmaceuticals (AGIO) announced on Tuesday the initiation of a phase I/II multicenter study of AG-221 in patients with advanced solid tumors that carry an … Continue Reading
Read Now
